Less Ads, More Data, More Tools Register for FREE

Pin to quick picksLunglife Ai Regulatory News (LLAI)

  • There is currently no data for LLAI

Holding(s) in Company

26 Mar 2024 13:49

RNS Number : 3768I
LungLife AI, INC
26 March 2024
Β 

TR-1: Standard form for notification of major holdings

Β 

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii:

LungLife AI Inc

1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)

Non-UK issuer

X

2. Reason for the notification (please mark the appropriate box or boxes with an "X")

An acquisition or disposal of voting rights

Β 

X

An acquisition or disposal of financial instruments

An event changing the breakdown of voting rights

Other (please specify) iii:

3. Details of person subject to the notification obligation iv

Name

Lombard Odier Asset Management (Europe) Limited

City and country of registered office (if applicable)

London, United Kingdom

4. Full name of shareholder(s) (if different from 3.) v

Name

Disclosure on behalf of accounts managed on a discretionary basis by Lombard Odier Investment Managers group.

City and country of registered office (if applicable)

5. Date on which the threshold was crossed or reached vi:

22.03.2024

6. Date on which issuer notified (DD/MM/YYYY):

25.03.2024

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8. A)

% of voting rights through financial instruments(total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights held in issuer (8.A + 8.B) vii

Resulting situation on the date on which threshold was crossed or reached

9.50%

9.50%

2,911,220

Position of previous notification (if

applicable)

Β 

8. Notified details of the resulting situation on the date on which the threshold was crossed or reached viii

A: Voting rights attached to shares

Class/type ofshares

ISIN code (if possible)

Number of voting rights ix

% of voting rights

Direct

(DTR5.1)

Indirect

Β (DTR5.2.1)

Direct

(DTR5.1)

Indirect

(DTR5.2.1)

USU5500L1128

1,642,857

5.36%

USU5500L1045

1,268,363

4.14%

SUBTOTAL 8. A

2,911,220

9.50%

Β 

Β 

B 1: Financial Instruments according to DTR5.3.1R (1) (a)

Type of financial instrument

Expirationdate x

Exercise/Conversion Period xi

Number of voting rights that may be acquired if the instrument is

exercised/converted.

% of voting rights

SUBTOTAL 8. B 1

Β 

Β 

B 2: Financial Instruments with similar economic effect according to DTR5.3.1R (1) (b)

Type of financial instrument

Expirationdate x

Exercise/Conversion Period xi

Physical or cash

Settlement xii

Number of voting rights

% of voting rights

Β 

SUBTOTAL 8.B.2

Β 

Β 

Β 

9. Information in relation to the person subject to the notification obligation (please mark the

applicable box with an "X")

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer xiii

X

Full chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entity (please add additional rows as necessary) xiv

Name xv

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

Β 

10. In case of proxy voting, please identify:

Name of the proxy holder

The number and % of voting rights held

The date until which the voting rights will be held

11. Additional information xvi

Β 

Place of completion

London, United Kingdom

Date of completion

25.03.2024

Β 

Β 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Β 
END
Β 
Β 
HOLDZGZFFVVGDZM
12
Date   Source Headline
29th May 20257:00 amRNSCancellation - LungLife AI, Inc.
27th May 20257:00 amRNSHolding(s) in Company
23rd May 20257:00 amRNSHolding(s) in Company
22nd May 20256:00 pmRNSLungLife AI
21st May 20257:01 amRNSHolding(s) in Company
21st May 20257:00 amRNSHolding(s) in Company
20th May 20255:15 pmRNSResult of Special Meeting
15th May 20257:00 amRNSHolding(s) in Company
15th May 20257:00 amRNSBlock listing Interim Review
14th May 20257:00 amRNSHolding(s) in Company
29th Apr 20257:00 amRNSNotice of Special Meeting
17th Apr 20257:00 amRNSLicense Agreement and Other Matters
10th Feb 20257:00 amRNSChange of Nominated Adviser and Joint Broker
3rd Feb 20257:00 amRNSOperational Update & Proposed Cancellation
19th Nov 20247:00 amRNSOperational update
15th Nov 20247:00 amRNSBlock listing Interim Review
25th Oct 20247:00 amRNSDirectorate Change
22nd Oct 20247:00 amRNSCancellation & Reissue Share Options, PDMR Notice
4th Oct 20247:00 amRNSOptions Cancellation and Re-issuance
2nd Oct 20247:00 amRNSLungLB® publication in peer-reviewed journal
2nd Sep 20247:00 amRNS-RData Supporting LungLB to be Presented at the AMP
22nd Aug 20247:00 amRNSHalf-year Report
16th Aug 20247:00 amRNSLCD coverage for Indeterminate Lung Nodules
15th Aug 20247:00 amRNSNotice of Results
5th Jun 20245:16 pmRNSResult of AGM
3rd Jun 202412:45 pmRNSConfirmation of AGM
15th May 20247:00 amRNSBlock Listing Six Monthly Return
2nd May 20244:04 pmRNSHolding(s) in Company
25th Apr 20247:00 amRNSPublication of Annual Report and Notice of AGM
17th Apr 20247:00 amRNSPresentation at NCI's EDRN Meeting
4th Apr 20247:00 amRNSPreliminary Audited Results
27th Mar 20247:00 amRNSNotice of Results
26th Mar 20241:49 pmRNSHolding(s) in Company
25th Mar 202410:33 amRNSHolding(s) in Company
22nd Mar 20249:39 amRNSAdmission of New Shares & PDMR Dealing
22nd Mar 20248:21 amRNSAdmission of New Shares & PDMR Dealing
21st Mar 20242:05 pmRNSResult of Special Meeting
6th Mar 20245:35 pmRNSPosting of Circular and Notice of Special Meeting
5th Mar 20247:00 amRNSResults of Placing and Subscription
4th Mar 20244:56 pmRNSProposed equity raise of approximately £1.8m
2nd Jan 20247:00 amRNSSuccessful validation study results for LungLB®
15th Nov 20237:00 amRNSBlock Listing Six Monthly Return
28th Sep 20237:00 amRNSClinical validation study update
14th Aug 20231:32 pmRNSDirector share purchases
8th Aug 20237:00 amRNSHalf-year Report
3rd Aug 20237:00 amRNSNotice of Results
6th Jun 20237:00 amRNSLungLB® study published in peer-reviewed journal
23rd May 20237:00 amRNSEnrolment completed for LungLB® validation study
15th May 20237:00 amRNSBlock Listing Six Monthly Return
4th May 20235:49 pmRNSResult of AGM
12

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.